With people living longer after being treated for prostate cancer, quality of life has become a concern when considering the treatment plan. Sometimes after radiation therapy, patients may experience problems that affect the urinary and bowel systems, along with sexual function. Stereotactic body radiotherapy (SBRT) is a type of radiation technique that delivers five high doses of radiation. At University of California at Los Angeles (UCLA), we have the option to administer SBRT in both our CT-guided and MRI-guided radiation machines. This trial aims to determine the most effective method for protecting the nerves and blood vessels essential for erectile function, utilizing a technique known as neurovascular sparing. This technique uses images (i.e., MRI) to map the neurovascular bundles of nerves and blood vessels, which are crucial for erectile function. "Adapting" the radiotherapy treatment for each of these five treatment sessions could enable a more precise delivery of your radiation treatment that is customized based on your internal anatomy immediately before the treatment starts. This is also a standard and low-risk intervention used in many different types of cancer. However, it is a very labor-intensive and time-consuming procedure that requires a team of experts to work together before each of your radiotherapy sessions. We are unsure if the increased complexity associated with this adaptive treatment reduces side effects.
The mechanism implicated in sexual function decline following radiotherapy involves injury to vascular structures surrounding the prostate which are critical for normal erectile function, namely the corpora cavernosa, internal pudendal arteries, and neurovascular bundles. These structures are all in close proximity to the prostate gland and are often included at least partially within the planning target volume margin of treatment plans. As noted above, these planning target volume (PTV) expansions were historically large due to the need to ensure adequate coverage of the target volume to achieve disease control although this likely came at the cost of higher rates of treatment-related toxicity. With enhanced technology for target visualization and intra-fraction motion management, it is technically feasible to reduce margins and spare surrounding normal tissue from receiving the full prescription dose while still treating the target volume with high confidence. Beyond reducing the isometric PTV expansion due to increased precision in radiation delivery with modern techniques, however, it is now technically feasible to crop out these sensitive Organs-at-risk (OARs) from the final PTV volume in order to further spare them from receiving excess dose. This process, referred to as neurovascular-sparing (NV-sparing), involves the fusion of an MRI and/or MR angiogram to standard radiation planning images to allow accurate contouring of the internal pudendal arteries and neurovascular bundles so that these can be intentionally spared. Daily online adaptive replanning may also play a role in ensuring appropriate coverage of the target volume and sparing of OARs as intended by the treatment plan. To date, no investigations have reported on the clinical or dosimetric outcomes of patients treated with an NV approach in conjunction with these other methods. Furthermore, specific dose constraints for these structures are largely unknown due to the lack of empiric evidence to guide selection.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
200
Use of adaptive radiotherapy
University of California at Los Angeles
Los Angeles, California, United States
RECRUITINGExpanded Prostate Cancer Index Composite (EPIC-26) sexual function Questionnaire
The primary endpoint is clinically relevant (≥24 point) decline in EPIC-26 sexual function domain scores at 24 months following treatment in patients randomized to NV-sparing SBRT relative to patients randomized to conventional SBRT without explicit NV-sparing.
Time frame: 24 months
Clinically relevant acute change in International Prostate Symptom Score (I-PSS) domain of EPIC-26.
Clinically relevant acute changes (from initiation to within 90 days after completion of SBRT) in IPSS of EPIC-26 patient-reported QOL. The International Prostate Symptom Score (I-PSS) is based on answers to seven questions concerning urinary symptoms and one question concerning quality of life. Answers are assigned points from 0 to 5. The total score range is from 0 -35. 0 indicating no symptoms to 35 indicating extremely symptomatic.
Time frame: From initiation to 90 days post treatment
Clinically relevant acute change in Sexual Health Inventory for Men (SHIM) domain of EPIC-26.
Clinically relevant acute changes (from initiation to within 90 days after completion of SBRT) in SHIM domain of EPIC-26 patient-reported QOL. The SHIM score range is from 5 to 25. Higher score indicates better erectile function.
Time frame: From initiation to 90 days post treatment
Clinically relevant chronic changes in IPSS, of EPIC-26.
Clinically relevant chronic changes (from initiation to within 90 days after completion of SBRT) in IPSS domain of EPIC-26 patient-reported QOL
Time frame: From initiation to 90 days post treatment
Clinically relevant chronic changes in SHIM, of EPIC-26.
Clinically relevant chronic changes (from initiation to within 90 days after completion of SBRT) in SHIM domain of EPIC-26 patient-reported QOL
Time frame: From initiation to 90 days post treatment
Gastric ulcer (GU) or Gastriointestinal (GI) toxicity
Incidence of GU or GI toxicity of at least grade 2 by the physician-reported CTCAE criteria.
Time frame: From initiation to 90 days post treatment
prostate specific antigen (PSA) completed response at 2 years
PSA completed response at 2 years, defined as proportion of patients with PSA \<20% of the pre-SBRT PSA.
Time frame: From initiation to 90 days post treatment
Biochemical Recurrence-Free Survival rate
Biochemical Recurrence-Free Survival rates at 5 years, where biochemical recurrence is defined as serum PSA levels 2 ng/mL higher than the post-treatment PSA nadir.
Time frame: From initiation to 90 days post treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.